Clinical Trial Update: Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients [NA]

View source ↗

Summary

A completed clinical trial evaluating fluorine-18-labeled fluoromisonidazole PET imaging to detect hypoxia in head and neck cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Head and Neck Cancer | NA | Status: COMPLETED | Results posted: 2020-07-10